Attached files
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 6, 2015
Tribute Pharmaceuticals Canada Inc.
(Exact name of registrant as specified in its charter)
|
Ontario, Canada
|
000-31198
|
Not Applicable
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
151 Steeles Avenue East, Milton, Ontario, Canada L9T 1Y1
(Address of principal executive offices) (Zip Code)
(519) 434-1540
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
Tribute Pharmaceuticals Canada Inc. (the “Company”) will hold a special meeting of shareholders on Wednesday, December 9, 2015. The materials mailed by the Company to its shareholders on November 6, 2015 in connection with such special meeting are filed under Item 9.01 herewith.
Item 9.01. Financial Statements and Exhibits.
d) Exhibits
The following exhibits are filed herewith:
|
Exhibit No.
|
|
Description
|
|
99.1
|
Notice of Special Meeting and Management Information Circular dated November 6, 2015
|
|
|
99.2
|
Letter of Transmittal
|
|
|
99.3
|
Voting Instruction Form
|
|
|
99.4
|
Form of Proxy
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TRIBUTE PHARMACEUTICALS CANADA INC.
|
|||
|
Date: November 9, 2015
|
By:
|
/s/ Scott Langille | |
| Scott Langille | |||
| Chief Financial Officer | |||
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
|
99.1
|
Notice of Special Meeting and Management Information Circular dated November 6, 2015
|
|
|
99.2
|
Letter of Transmittal
|
|
|
99.3
|
Voting Instruction Form
|
|
|
99.4
|
Form of Proxy
|